Misiu and Ohm and other science-minded others, here's a question that will be pure speculation. But given our data, I'm sure there's a lot of speculating going on.

So, given Leronlimab was called into service as the 4th line of defense,
and given many of our patients received less than 700 mg -

Could we make an educated guess on what the expected outcomes would be if we were 1st line treatment at 700 mg?

Given LL is so safe, I assume this efficacy estimate will be what drives any partnership talks.